CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for SciGen Limited is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

SciGen Limited
152 Beach Road, The Gateway, # 26 07 08
Phone: +65 67796638p:+65 67796638 189721  Singapore Fax: +65 67793784f:+65 67793784

This company was Merged or Acquired on 7/18/2018.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
SciGen Ltd is a biotechnology company. The Company, along with its subsidiaries, is involved in the sales, marketing and development of pharmaceutical and recombinant technology derived products. Its geographical segments include Singapore, involving in corporate office functions and sales and marketing; Australia, Korea, Thailand, Philippines, engaging in sales and marketing activities; China, engaging in regulatory activities, and Others, involving operations carried on in Indonesia, Pakistan, Vietnam, Hong Kong, Myanmar, Malaysia and profit sharing income on sale of insulin. Its portfolio consists of biosimilar products, such as rhuman growth hormone and rhuman insulin. The Company offers a range of products, including SciTropin A, SciBenclamide, SciLodipine, SciLosar, SciLin, SciTrozole, Heri Injection, Zinc-S, Zinc-I, Gensupen, Insupen, Zonegran, Alsense and SciLocyte. In addition, the Company in-licenses and distributes pharmaceutical products and medical devices.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201712/31/2017Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer MarekDziki 8/7/2018 6/6/2016
Chief Financial Officer Adam T.Polonek 8/7/2018 6/26/2008
Group Financial Controller, Executive Director Yvonne L.Guat 9/8/2017 2/1/2010
10 additional Officers and Directors records available in full report.

Business Names
Business Name
SciGen Limited
SIE

General Information
Stock Exchange: ASX
Fax Number: +65 67793784


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023